Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Synergistic Bcl-2 inhibition by ABT-737 and cyclosporine A.

Cippà PE, Kamarashev J, Chen J, Kraus AK, Segerer S, Feldmeyer L, Fehr T.

Apoptosis. 2013 Mar;18(3):315-23. doi: 10.1007/s10495-012-0778-2.

PMID:
23208368
2.

Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin-NFAT pathway.

Cippà PE, Kraus AK, Lindenmeyer MT, Chen J, Guimezanes A, Bardwell PD, Wekerle T, Wüthrich RP, Fehr T.

Cell Death Dis. 2012 Apr 19;3:e299. doi: 10.1038/cddis.2012.38.

3.

γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.

Séveno C, Loussouarn D, Bréchet S, Campone M, Juin P, Barillé-Nion S.

Breast Cancer Res. 2012 Jun 15;14(3):R96.

4.

Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins.

Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Böck BC, Macher-Goeppinger S, Radlwimmer B, Wiestler OD, Herold-Mende C, Roth W.

Oncogene. 2008 Nov 6;27(52):6646-56. doi: 10.1038/onc.2008.259. Epub 2008 Jul 28.

PMID:
18663354
5.

Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.

Karlsson H, Lindqvist AC, Fransson M, Paul-Wetterberg G, Nilsson B, Essand M, Nilsson K, Frisk P, Jernberg-Wiklund H, Loskog A.

Cancer Gene Ther. 2013 Jul;20(7):386-93. doi: 10.1038/cgt.2013.35. Epub 2013 Jun 21. Erratum in: Cancer Gene Ther. 2013 Dec;20(12):702. Karlsson, S C H [corrected to Karlsson, H];Loskog, S I A [corrected to Loskog, A].

PMID:
23788110
6.

The BH3-mimetic ABT-737 inhibits allogeneic immune responses.

Cippà PE, Kraus AK, Edenhofer I, Segerer S, Chen J, Hausmann M, Liu Y, Guimezanes A, Bardwell PD, Wüthrich RP, Fehr T.

Transpl Int. 2011 Jul;24(7):722-32. doi: 10.1111/j.1432-2277.2011.01272.x. Epub 2011 May 25.

7.

Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.

Lieber J, Kirchner B, Eicher C, Warmann SW, Seitz G, Fuchs J, Armeanu-Ebinger S.

Pediatr Blood Cancer. 2010 Dec 1;55(6):1089-95. doi: 10.1002/pbc.22740.

PMID:
20680965
8.

The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.

Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A.

Clin Cancer Res. 2007 Dec 1;13(23):7191-8.

9.

The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.

Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N.

Hepatology. 2010 Oct;52(4):1310-21. doi: 10.1002/hep.23836.

PMID:
20799354
10.

Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.

Kunami N, Katsuya H, Nogami R, Ishitsuka K, Tamura K.

Anticancer Res. 2014 Oct;34(10):5287-94.

PMID:
25275021
11.

[Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells].

Chen ZJ, Zhang B, Pan SH, Zhao HM, Zhang Y, Feng WH, Li YY, Cao XC.

Zhonghua Zhong Liu Za Zhi. 2011 Dec;33(12):891-5. Chinese.

PMID:
22340096
12.

Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737.

Ishitsuka K, Kunami N, Katsuya H, Nogami R, Ishikawa C, Yotsumoto F, Tanji H, Mori N, Takeshita M, Miyamoto S, Tamura K.

Cancer Lett. 2012 Apr 28;317(2):218-25. doi: 10.1016/j.canlet.2011.11.030. Epub 2011 Dec 2.

PMID:
22138435
13.

The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.

High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, Vikstrom IB, Roberts AW, Lock RB.

Mol Pharmacol. 2010 Mar;77(3):483-94. doi: 10.1124/mol.109.060780. Epub 2009 Dec 28.

14.

ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.

Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T.

Br J Haematol. 2008 Jan;140(2):181-90. Epub 2007 Nov 20.

PMID:
18028486
15.

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM, Lock RB, Reynolds CP.

Blood. 2007 Sep 15;110(6):2057-66. Epub 2007 May 29.

16.

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA.

Blood. 2008 Oct 1;112(7):2906-16. doi: 10.1182/blood-2007-12-130781. Epub 2008 Jun 30.

17.

Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells.

Reynoso D, Nolden LK, Yang D, Dumont SN, Conley AP, Dumont AG, Zhou K, Duensing A, Trent JC.

Mol Oncol. 2011 Feb;5(1):93-104. doi: 10.1016/j.molonc.2010.10.003. Epub 2010 Oct 16.

18.

Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737.

Song JH, Kraft AS.

Cancer Res. 2012 Jan 1;72(1):294-303. doi: 10.1158/0008-5472.CAN-11-3240. Epub 2011 Nov 11.

19.

Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad.

Yin S, Dong Y, Li J, Fan L, Wang L, Lu J, Vang O, Hu H.

Apoptosis. 2012 Apr;17(4):388-99. doi: 10.1007/s10495-011-0687-9.

PMID:
22179721
20.

Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors.

Whitecross KF, Alsop AE, Cluse LA, Wiegmans A, Banks KM, Coomans C, Peart MJ, Newbold A, Lindemann RK, Johnstone RW.

Blood. 2009 Feb 26;113(9):1982-91. doi: 10.1182/blood-2008-05-156851. Epub 2008 Dec 5.

Supplemental Content

Support Center